Cargando…

GENETIC RISK FACTORS IN SEVERE, NONSEVERE AND ACUTE PHENOTYPES OF CENTRAL SEROUS CHORIORETINOPATHY

PURPOSE: To study genetic predispositions and differences between severe chronic central serous chorioretinopathy (cCSC), nonsevere cCSC, and acute central serous chorioretinopathy (aCSC). METHODS: One hundred seventy-three severe cCSC patients, 272 nonsevere cCSC patients, 135 aCSC patients, and 1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohabati, Danial, Schellevis, Rosa L., van Dijk, Elon H. C., Fauser, Sascha, den Hollander, Anneke I., Hoyng, Carel B., De Jong, Eiko K., Yzer, Suzanne, Boon, Camiel J. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Retina 2020
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447124/ https://www.ncbi.nlm.nih.gov/pubmed/31815877 http://dx.doi.org/10.1097/IAE.0000000000002682

Ejemplares similares

CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Mohabati, Danial, et al.
Publicado: (2020)

Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy
por: Mohabati, Danial, et al.
Publicado: (2018)

Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy
por: Mohabati, Danial, et al.
Publicado: (2018)

Risk of Recurrence and Transition to Chronic Disease in Acute Central Serous Chorioretinopathy
por: Mohabati, Danial, et al.
Publicado: (2020)

Exome sequencing in patients with chronic central serous chorioretinopathy
por: Schellevis, Rosa L., et al.
Publicado: (2019)

Exome sequencing in families with chronic central serous chorioretinopathy
por: Schellevis, Rosa L., et al.
Publicado: (2019)

Fundus autofluorescence abnormalities can predict fluorescein angiography abnormalities in patients with chronic central serous chorioretinopathy
por: Mohabati, Danial, et al.
Publicado: (2023)

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Feenstra, Helena M. A., et al.
Publicado: (2023)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung, Wing H, et al.
Publicado: (2016)

Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life
por: Breukink, Myrte B, et al.
Publicado: (2016)

Central serous chorioretinopathy in primary hyperaldosteronism
por: van Dijk, Elon H. C., et al.
Publicado: (2016)

Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy
por: van Rijssen, Thomas J., et al.
Publicado: (2018)

Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial
por: Breukink, Myrte B., et al.
Publicado: (2015)

Systemic complement activation in central serous chorioretinopathy
por: van Dijk, Elon H. C., et al.
Publicado: (2017)

Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea
por: van Dijk, Elon H. C., et al.
Publicado: (2017)

Sex Hormones in Males and Females with Active Central Serous Chorioretinopathy
por: Brinks, Joost, et al.
Publicado: (2023)

Long‐term follow‐up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser
por: van Rijssen, Thomas J., et al.
Publicado: (2021)

Central serous chorioretinopathy in active endogenous Cushing’s syndrome
por: Brinks, Joost, et al.
Publicado: (2021)

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy
por: van Rijssen, Thomas J., et al.
Publicado: (2018)

Stress and vision-related quality of life in acute and chronic central serous chorioretinopathy
por: Kumar, Meenakshi, et al.
Publicado: (2020)

Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data
por: Subhi, Yousif, et al.
Publicado: (2021)

Evaluation of Choroidal Layer Thickness in Central Serous Chorioretinopathy
por: Hanumunthadu, Daren, et al.
Publicado: (2019)

Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities
por: Brinks, Joost, et al.
Publicado: (2022)

Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy
por: Hosoda, Yoshikatsu, et al.
Publicado: (2019)

Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3
por: Feenstra, Helena M. A., et al.
Publicado: (2022)

Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy
por: Matet, A., et al.
Publicado: (2020)

SINGLE-SESSION BILATERAL REDUCED-SETTINGS PHOTODYNAMIC THERAPY FOR BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Pauleikhoff, Laurenz J.B., et al.
Publicado: (2023)

Cushing’s Syndrome and Hypothalamic–Pituitary–Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy
por: van Haalen, Femke M., et al.
Publicado: (2018)

Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence
por: Pfau, Maximilian, et al.
Publicado: (2021)

Management of central serous chorioretinopathy: Expert panel discussion
por: Chhablani, Jay, et al.
Publicado: (2018)

Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification
por: Jain, Manish, et al.
Publicado: (2022)

The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy
por: Brinks, Joost, et al.
Publicado: (2021)

Response to Letter to the Editor From Behar-Cohen et al.: The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy
por: Brinks, Joost, et al.
Publicado: (2021)

Increased pro-MMP9 plasma levels are associated with neovascular age-related macular degeneration and with the risk allele of rs142450006 near MMP9
por: Lauwen, Susette, et al.
Publicado: (2021)

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Analysis of hemopexin plasma levels in patients with age-related macular degeneration
por: Lauwen, Susette, et al.
Publicado: (2022)

Scientific Literature Database Coverage of Randomized Clinical Trials for Central Serous Chorioretinopathy
por: Boberg-Ans, Lars C., et al.
Publicado: (2023)

Cadherin 5 is Regulated by Corticosteroids and Associated with Central Serous Chorioretinopathy
por: Schubert, Carl, et al.
Publicado: (2014)

The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification
por: van Dijk, Elon H. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gr8hmgo1erci6holrmoe0h700f